Moreover, in a subgroup analysis performed in a phase II trial investigating the efficacy of tivantinib (MET-inhibitor) versus placebo as second-line treatment after sorafenib, Santoro et al. showed an association between MET overexpression and poor HCC prognosis [63]. This evidence concerns the gene MET and hepatocellular carcinoma.